An Early Phase 1 interventional study of Low dose KL001 and Middle dose KL001 in Hemophilia B Without Inhibitor, sponsored by Affiliated Hospital of Guangdong Medical University. Not yet recruiting. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-11-09.
Sponsored by Affiliated Hospital of Guangdong Medical University · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL001 injection solution in hemophilia B subjects with ≤2 IU/dl residual FIX levels.
This is an open- label, non- randomized, uncontrolled, dose-escalation pilot study to evaluate the safety and efficacy of KL001 injection solution in hemophilia B subjects with ≤2 IU/dl residual FIX levels. Nine subjects will be enrolled and administered with three different doses of KL001. Subjects will provide informed consent and then undergo screening assessments up to 1 month prior administration of KL001. All subjects will undergo 52 weeks safety observation and will be encouraged to enroll in an extension study to evaluate long- term safety of KL001 for total 5 years.
292 studies on the registry are indexed under Hemophilia B; 51 are open to participants now.
This study's planned enrollment of 9 is below the median of 26 across 171 interventional studies indexed under Hemophilia B.
Browse Hemophilia B studies →Affiliated Hospital of Guangdong Medical University is the lead sponsor of 12 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be dosed with three different dose of KL001 injection solution at 2.5x10\^12 vg/kg to 1.0x10\^13 vg/kg.
Drug: Low dose KL001 · Drug: Middle dose KL001 · Drug: High dose KL001
Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
Also known as: rAAV vector
Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
Also known as: rAAV vector
Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
Also known as: rAAV vector
Incidence of treatment- related adverse events
Number and severity of adverse events and serious adverse events and relationship to KL001
Time frame: Infusion to the completion of study, about 52 weeks
Antibody against KL001 AAV vector capsid protein
Immune response against AAV capsid will be evaluated by measurement of the total antibody and neutralizing antibody against AAV capsid protein in plasma samples collected at multiple timepoints after dosing up to 52 weeks
Time frame: Infusion to the completion of study, about 52 weeks
Factor IX inhibitor
Development of inhibitor against vector-derived Factor IX protein will be measured using bethesda method.
Time frame: Infusion to the completion of study, about 52 weeks
vector-derived FIX: C activity levels
Peak and steady-state activity levels of vector-derived FIX: C
Time frame: From dosing day to week 52
The annualized bleeding rate Before and After KL001 Infusion
The annualized bleeding rate (ABR) will be calculated for all subjects through Week 52
Time frame: From dosing day to week 52
The annualized use of FIX
The use of on-demand FIX replacement therapy was recorded by dose (IU/kg) administered, and the annualized use of FIX replacement therapy was calculated for all subjects through Week 52.
Time frame: From dosing day to week 52
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2023; primary completion for Sep 2024, 9 months later.
Of 15 phase 1 interventional studies under Hemophilia B, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 42. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: KL001
Affiliated Hospital of Guangdong Medical University